KinaseAdvisor is the most sensitive assay panel available for kinases, a family of over 500 enzymes involved in regulating cell behavior in the human body
NovaScreen Biosciences, a Caliper Life Sciences company, has launched its new KinaseAdvisor screening panel of 48 protein kinase assays.
KinaseAdvisor is the most sensitive assay panel available for kinases, a family of over 500 enzymes involved in regulating cell behavior in the human body.
Profiling a drug candidate's activity against a wide variety of kinases is crucial to understanding potential safety and efficacy issues.
"Activity that goes unnoticed in other kinase profiling assay panels is routinely detected and flagged by the KinaseAdvisor screening panel," said Peter Carlson, vice president of NovaScreen.
"This information could be important from a safety standpoint or could lead to a new drug candidate".
NovaScreen performs the KinaseAdvisor assays on the Caliper LabChip 3000 platform, which uses electrophoresis instead of antibodies as the basis of the assay.
Electrophoretic separation of assay components is more sensitive and yields more highly reproducible data.
In addition, researchers can examine compounds against a broad representation of the human kinome, creating an opportunity for NovaScreen clients to better characterise activity and possibly identify additional therapeutic targets.
"The extraordinary quality and reproducibility of the KinaseAdvisor data means our clients receive the same answer every time the experiment is conducted," continued Carlson.
"This level of data quality is in high demand as the industry continues to struggle with bringing drugs to market faster and more cost effectively.
"To meet this demand, we are currently developing a second panel with an additional 48 kinase assays".
NovaScreen Biosciences is a provider of drug discovery and development services and products, with a focus on in vitro (laboratory-based) screening assays and in silico (computer-based) predictive screening tools.
Services and products are provided to more than 180 clients worldwide, including a majority of the leading drug and biotechnology companies.
